Artiva Biotherapeutics, Inc. (ARTV) Form 8-K — Sep 11, 2026
$ARTVForm 8-KItems 5.02, 5.07, 9.01Filed Sep 11, 2026, 4:21 PM ET0001193125-26-389308Original filing
Artiva Biotherapeutics stockholders approved an amendment to the 2024 Equity Incentive Plan at the September 8, 2026 annual meeting, increasing shares authorized for issuance by 5,097,095 and adding pre-funded warrant shares to the annual automatic reserve increase calculation. The plan's total share reserve now stands at 13,328,057 shares, with a 5% automatic annual increase running each January 1 from 2027 through 2034. On the 48,885,777 shares outstanding as of the July 20 record date, stockholders elected Brian Daniels, M.D. and Laura Stoppel, Ph.D.
Key figures
- Shares Outstanding
- 48885777
- Record Date
- 2026-07-20
- Annual Meeting Date
- 2026-09-08
- Total Plan Share Reserve
- 13328057
- Automatic Annual Increase
- 5% of Share Reserve Increase Stock each January 1 from 2027 through 2034
- Equity Plan Share Increase
- 5097095
- Kpmg Ratification Votes For
- 44000762
- Plan Amendment Votes Against
- 6816989
- Non Employee Director Comp Limit
- 750000
- Director Election Votes For Daniels
- 33591967
- Director Election Votes For Stoppel
- 33862513
- Non Employee Director Comp Limit First Year
- 1000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.